FIMMCYTE
FimmCyte develops a novel immune system-based treatment, which demonstrated positive results through early preclinical studies.
FIMMCYTE
Social Links:
Industry:
Biotechnology Medical
Founded:
2022-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.fimmcyte.com
Total Employee:
1+
Status:
Active
Total Funding:
1.24 M CHF
Similar Organizations
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
Investors List
Venture Kick
Venture Kick investment in Grant - FimmCyte
InnoBooster
InnoBooster investment in Grant - FimmCyte
InnoSuisse
InnoSuisse investment in Grant - FimmCyte
Official Site Inspections
http://www.fimmcyte.com
- Host name: 221.171.147.34.bc.googleusercontent.com
- IP address: 34.147.171.221
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "FimmCyte"
FimmCyte - Crunchbase Company Profile & Funding
Organization. FimmCyte . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... FimmCyte closed its last …See details»
New Portfolio Start-Up: FimmCyte - USZ
Apr 11, 2022 FimmCyte will accelerate the path towards an endometriosis cure with the right understanding and technological edge that can lead towards a successful future. To support the progress of curing women’s health, …See details»
FimmCyte - LinkedIn
FimmCyte is changing that. They’re developing a disease-modifying therapy for endometriosis, targeting the condition’s underlying drivers to deliver long-lasting relief, better fertility ...See details»
FimmCyte Company Profile 2024: Valuation, Funding & Investors
FimmCyte General Information Description. Operator of a biotechnology company intended to accelerate the path toward an endometriosis cure. The company is developing treatments to …See details»
About – FimmCyte
<img fetchpriority="high" fetchpriority="high" decoding="async" width="244" height="300" src="https://fimmcyte.com/wp-content/uploads/2024/08/shilaih_pic-244x300.jpg ...See details»
FimmCyte - Company Profile - Tracxn
Oct 22, 2024 FimmCyte - Developer of therapeutics to treat endometriosis. Raised funding over 2 rounds from 4 investors. Founded by Valentina Vongrad in the year 2022. FimmCyte has 24 …See details»
FimmCyte AG Company Profile | Basel, BASEL-STADT, Switzerland ...
Find company research, competitor information, contact details & financial data for FimmCyte AG of Basel, BASEL-STADT. Get the latest business insights from Dun & Bradstreet.See details»
FimmCyte – novel endometriosis treatment | Gebert Rüf Stiftung
Oct 2, 2022 At FimmCyte our vision is to develop the first disease modifying treatment for endometriosis. Every tenth woman has endometriosis, but besides pain management and …See details»
FimmCyte - Crunchbase
FimmCyte develops a novel immune system-based treatment, which demonstrated positive results through early preclinical studies.See details»
Meet the start-ups: FimmCyte - BioInnovation Institute
Sep 20, 2022 Endometriosis affect s more than 1 in 10 women of reproductive age worldwide. F or many of these women, it means a life with excruciating pain, infertility, or other severe …See details»
From lab to life-changing: how FimmCyte is on track to transform …
Nov 27, 2024 <p>Thanks to advocates’ endless campaigning and increased clinical attention, endometriosis is finally beginning to receive the attention it deserves. ‘Endo Warriors’ – the …See details»
FimmCyte AG - top100startup.ch
News. 17.09.2024 The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100); 29.02.2024 FimmCyte secures 1 million CHF investment for Non …See details»
FimmCyte: The Venture Leader Biotech developing the first disease ...
Aug 23, 2022 This fall, the Venture Leaders Biotech will represent Swiss innovation in the United States. To select the 10 featured startups, a jury of professional investors and medtech …See details»
FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund
Feb 29, 2024 FimmCyte is a spin-off company from the University of Zürich and the University Hospital Zürich, the Lab of Prof. Brigitte Leener, and was founded in 2022 by Valentina …See details»
FimmCyte Joins BII’s Venture House Program to Continue Work on …
Sep 5, 2023 Danish biotech startup FimmCyte is joining BioInnovation Institute’s (BII) Venture House, a program designed to further support former BII Venture Lab companies in their next …See details»
FimmCyte secures 1 million CHF investment for Non-Hormonal ...
Feb 29, 2024 FimmCyte participated in Venture Leaders Biotech in 2022 as well as won the last stage of the Venture Kick program in the same year. "Venture Leaders gave us the chance to …See details»
FimmCyte at the Swiss Biotech Day
At FimmCyte our vision is to create the first disease modifying treatment for endometriosis. Every tenth woman has endometriosis, but besides pain management and surgery there are no …See details»
01 Dec - FimmCyte
What is the Solution? FimmCyte is at the forefront of a new approach to endometriosis treatment, developing the first disease-modifying therapy that tackles the root causes of the condition. By …See details»
FimmCyte wins CHF 150,000 to advance their non-hormonal, …
To address this unmet medical need, FimmCyte has engineered a first-in-class, disease-modifying treatment that has shown efficacy in eliminating endometriosis in the lab and animal …See details»